Combigene

July – September 2023
• Net sales: TSEK 992 (5,213).
• Other operating revenues: TSEK 173 (8,285).
• Profit from financial items: TSEK -8,403 (3,953).
• Earnings per share: SEK -0.42 (0.20).

January – September 2023
• Net sales: TSEK 4,948 (21,354).
• Other operating revenues: TSEK 588 (20,888).
• Profit from financial items: TSEK -29,305 (5,785).
• Earnings per share: SEK -1.48 (0.29).
• Cash and cash equivalents: TSEK 107,187 (144,940).

Events during the period
• The Epilepsy Project progresses through optimization activities in preparation for in-human studies. (September 5)
• CombiGene chooses CDMO partner for the COZY01 pain project. (September 15)

Events after the end of the period
• Spark Therapeutics terminates collaboration agreement for the epilepsy project CG01 with CombiGene. (October 14)
• CombiGene and Zyneyro choose initial indication in the COZY01 pain project (October 26)
• CombiGene chooses Charles River as preclinical toxicology partner for the COZY01 pain project. (October 31)